| HOME >> BIOLOGY >> TECHNOLOGY |
-----------------------------------------------------------------------
23,356 24,580
$ 28,050 $ 41,770
-------------------------------------------------------------------------
-------------------------------------------------------------------------
VASOGEN INC.
(A DEVELOPMENT STAGE COMPANY)
Consolidated Statements of Operations, Deficit and Comprehensive Income
(In thousands of Canadian dollars, except per share amounts)
-------------------------------------------------------------------------
Period from
December 1,
1987 to
Years ended November 30, November 30,
2007 2006 2005 2007
-------------------------------------------------------------------------
Expenses:
Research and development $ 12,039 $ 32,732 $ 71,421 $ 238,917
General and
administration 14,259 19,251 22,126 117,228
Foreign exchange loss
(gain) 1,977 104 (719) 10,970
-------------------------------------------------------------------------
Loss before the undernoted (28,275) (52,087) (92,828) (367,115)
Interest expense on senior
convertible notes payable (5) (930) (344) (1,279)
Accretion in carrying value
of senior convertible
notes payable (728) (7,824) (1,742) (10,294)
Amortization of deferred
financ
'/>"/>
| SOURCE Vasogen Inc. Copyright©2008 PR Newswire. All rights reserved |